An Open-label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers
NCT #
NCT04553692
Condition(s)
Colorectal Cancer
Molecular Target(s)
Not Required
Drug Classification(s)
engineered, humanized, specific anti-DR5 targeting pentameric IgM antibody
Agents(s)
IGM-8444 and several SOC therapies
Phase(s)
I
Mechanism of Action
IGM-8444 is an agonist antibody to DRS on the cell surface. Binding of the antibody to DRS mimics the interaction between DRS and its natural ligand, TRAIL. Crosslinking activates the death receptor pathway leading to induction of apoptosis. Birinipant is a small molecule SMAC mimetic. SMAC is also an activator of apoptosis. Therefore, there could be a stronger apoptotic signal if the two agents are combined.
Purpose
- How much of the study agent alone or in combination with other drugs can be given with an acceptable level of side effects
- The effects of the study agent alone or in combination with other drugs (good and bad)
- How much of the study agent alone or in combination with other drugs is absorbed into the blood and how fast it is removed
- How the body responds to the study agent alone or in combination with other drugs for a particular type of cancer
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.